Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06025786
Other study ID # BNP Quasi Experimental Study
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2021
Est. completion date June 30, 2026

Study information

Verified date July 2023
Source Aga Khan University
Contact Sajid Bashir Soofi, MD, CPSP
Phone +923002769398
Email sajid.soofi@aku.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to evaluate the impact of Benazir Nashonuma Program (BNP) on prevalence of stunting among under-five children in low income setting of Pakistan. The research question that the study aims to answer is: Is there any change in the prevalence of stunting among under-five children in districts where Benazir Nashonuma Program (BNP) is established compared to districts where BNP is not established? Districts where BNP is functional, and women and children are receiving the intervention will be compared at baseline and end line with control districts where conventional reproductive care services are given. Prevalence of stunting among under-five children will be compared along with other nutritional and growth status indicators over a period of 4 years.


Description:

Maternal and child malnutrition is a significant public health challenge, with 40% of under five children being stunted in Pakistan. Stunting is associated with morbidity and mortality with detrimental effects on the physical, social and cognitive development of children. The two key determinants include maternal undernutrition during in-utero and poor infant and child feeding practices in the first two years of life. The opportunity to improve maternal, infant, and child outcomes is provided by the interventions aimed at improving maternal and child nutrition throughout the first 1000 days, known as "window of opportunity". In this study, the investigators aim to assess the effectiveness of the Benazir Nashonuma Programme (BNP) on stunting reduction and related maternal and child health outcomes and to determine the uptake of BNP related services in the intervention districts in all provinces and regions of Pakistan. The study will achieve the following objectives: Primary Objective • To determine the baseline to end-line change in the prevalence of stunting among children 0-59 months of age among low income settings Secondary Objectives For under-five children: To determine the baseline to end-line change in the - Prevalence of wasting among children 0-59 months of age - Prevalence of underweight children 0-59 months of age - Prevalence of Moderate Acute Malnutrition (MAM) among children 0-59 months of age - Prevalence of Severe Acute Malnutrition (SAM) among children 0-59 months of age - Prevalence of 0-23 months old children meeting Infant and Young Child Feeding (IYCF) indicators including exclusive breastfeeding, complementary feeding, dietary diversity, minimum acceptable diet and minimum meal frequency. - Proportion of children 0-59 months of age who received all recommended vaccinations according to the national immunization schedule. For Women of Reproductive Age (15- 49 years): To determine the baseline to end-line change in the - BMI (body mass index) and prevalence of underweight women of reproductive age (WRA) - Reproductive services uptake by WRA - Minimum dietary diversity among WRA - Percentage of households that experienced food insecurity. A quasi-experimental study with baseline and end-line cross-sectional surveys will be conducted in 18 districts of the four provinces and two administrative areas of Pakistan. The intervention districts includes Shaheed Benazir Abad and Dadu from Sindh, Rajanpur from Punjab, Lasbela and Harnai from Balochistan, Upper Dir and Tank from Khyber Pakhtunkhwa, Diamer from Gilgit Baltistan and Bagh from Azad Jammu and Kashmir. Their control districts are Sangarh, Naushero Feroze, Bahawalnagar, Sibbi, Sherani, Shangla, D. I. Khan, Shigar and Muzaffarbad respectively. The study will employ a two-stage cluster sampling to enroll children 0-59 months of age and their mothers/caregivers from the 13,200 households (734 per district). The primary (PSUs) and secondary sampling units (SSUs) will include villages and households respectively.


Recruitment information / eligibility

Status Recruiting
Enrollment 13200
Est. completion date June 30, 2026
Est. primary completion date December 20, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 1 Day to 59 Months
Eligibility All those households are eligible to be included in the study who have: - An under-five child with a mother registered with Benazir Income Support Program (BISP) - Both available at the time of interview Exclusion criteria includes: • Mother of the child who is not a woman of reproductive age, i.e., less than 15 years or greater than 49 years

Study Design


Intervention

Combination Product:
Benazir Nashonuma Program (BNP)
Benazir Nashonuma Program (BNP) Dietary supplement for pregnant women and lactating mothers during the first six months of lactation: Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy Dietary supplement for children aged 6-23 months: Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy. Conditional Cash Transfer (CCT): This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months

Locations

Country Name City State
Pakistan Aga Khan University Karachi Sindh

Sponsors (3)

Lead Sponsor Collaborator
Aga Khan University Bill and Melinda Gates Foundation, International Food Policy Research Institute

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Baseline to end-line change in the prevalence of stunting among children 0-59 months of age Height-for-age =-2 SD of the WHO Child growth standards median 3 years (on study completion)
Secondary Baseline to end-line change in the prevalence of underweight women of reproductive age (15-49 years) WRA with a Body Mass Index (BMI) less than 18.5 kg/m2 will be considered underweight 3 years (on study completion)
Secondary Baseline to end-line change in the prevalence of wasting among children 0-59 months of age Weight-for-height =-2 SD of the WHO Child growth standards median 3 years (on study completion)
Secondary Baseline to end-line change in the prevalence of food insecurity status at household level Food Insecurity Experience Scale (FIES) by Food and Agriculture Organization (FAO) is experience-based measures of household or individual food security. It consists of eight questions regarding people's access to adequate food in last 12 months due to lack of money or other resources. Food insecurity is reported as mild, moderate and severe. 3 years (on study completion)
Secondary Baseline to end-line change in the number of antenatal care (ANC) visits during pregnancy Number of antenatal care (ANC) visits done during the preceding pregnancy, leading to a live birth within the last two years. 3 years (on study completion)
Secondary Baseline to end-line change in the prevalence of institutional deliveries Number of women who gave birth at a healthcare facility during the preceding pregnancy, leading to a live birth within the last two years. 3 years (on study completion)
Secondary Baseline to end-line change in the prevalence of skilled birth attendance Number of women whose birth was attended by a skilled health personnel during the preceding pregnancy, leading to a live birth within the last two years. 3 years (on study completion)
Secondary Baseline to end-line change in prevalence of utilization of iron folic acid (IFA) during pregnancy Consumption of iron folic acid tablets during pregnancy 3 years (on study completion)
Secondary Baseline to end-line change in the prevalence of Minimum dietary diversity for women (MDDW) Consumption of at least five out of the ten food groups during the previous day and night (24 hours) 3 years (on study completion)
Secondary Baseline to end-line change in the prevalence of infants who were ever breastfed Number of infants who were breastfed at least once 3 years (on study completion)
Secondary Baseline to end-line change in the prevalence of exclusive breastfeeding among infants 0-5 months of age Number of infants who were fed exclusively with breast milk during the previous day 3 years (on study completion)
See also
  Status Clinical Trial Phase
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT03341338 - Genes-in-Action - Hepcidin Regulation of Iron Supplementation
Completed NCT00060398 - Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Active, not recruiting NCT02101944 - Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Not yet recruiting NCT06309641 - Methemoglobinemia Following Intravenous Iron Treatment
Completed NCT03822884 - Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers Phase 1
Completed NCT02930850 - Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation N/A
Completed NCT02912533 - A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02912494 - A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02603250 - Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda N/A
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Completed NCT02310113 - Transfusion and Skeletal Muscle Tissue Oxygenation N/A
Completed NCT01922479 - Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure Phase 4
Withdrawn NCT01934842 - A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate N/A
Completed NCT01693029 - Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Phase 3
Completed NCT01432717 - Study of ACE-536 in Healthy Postmenopausal Women Phase 1